SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade

• Main Authors: Mingxia Zhao (Author), Wenjie Guo (Author), Yuanyuan Wu (Author), Chenxi Yang (Author), Liang Zhong (Author), Guoliang Deng (Author), Yuyu Zhu (Author), Wen Liu (Author), Yanhong Gu (Author), Yin Lu (Author), Lingdong Kong (Author), Xiangbao Meng (Author), Qiang Xu (Author), Yang Sun (Author)
• Format: Book
• Published: Elsevier, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role in both tumor growth promotion and T-cell inactivation. Its allosteric inhibitor SHP099 is known to inhibit cancer cell growth both in vitro and in vivo. However, whether SHP099-mediated SHP2 i...